About this Research Topic
In the current landscape of targeted therapies, the exploration of novel targets and biomarkers holds paramount importance in advancing drug development and treatment modalities. The term "solid tumor targets" refers to molecular structures or signaling pathways within or around tumor cells that possess specific functions and play crucial regulatory roles in tumor growth and development. Pharmacology, on the other hand, is the scientific study of the interactions between drugs and organisms, encompassing processes such as drug absorption, distribution, metabolism, and excretion, as well as the effects and side effects that drugs produce in organisms.
Beyond the identification of novel targets and biomarkers, a pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival. Such insights are instrumental in crafting drugs that can adeptly target these interactions and impede cancer progression. Furthermore, the trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials. These trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects.
The Research Topic issue on " Novel biomarkers in solid tumors and related medicine therapy" serves as a forum for disseminating the latest research findings, deliberating challenges, and charting future research directions in this domain. Submissions spanning various disciplines are encouraged, including pharmacology basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development. By fostering a collaborative community of researchers and clinicians, we aim to expedite the development of innovative drugs and biomarkers for the treatment of solid tumors.
• A pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival
• The trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials
• Trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects
• Pharmacology basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development based on biomarkers of solid tumors.
• Explore the pharmacological mechanisms of drug therapy for solid tumors according to relevant targets and pathways.
Beyond the identification of novel targets and biomarkers, a pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival. Such insights are instrumental in crafting drugs that can adeptly target these interactions and impede cancer progression. Furthermore, the trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials. These trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects.
The Research Topic issue on " Novel biomarkers in solid tumors and related medicine therapy" serves as a forum for disseminating the latest research findings, deliberating challenges, and charting future research directions in this domain. Submissions spanning various disciplines are encouraged, including pharmacology basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development. By fostering a collaborative community of researchers and clinicians, we aim to expedite the development of innovative drugs and biomarkers for the treatment of solid tumors.
• A pivotal facet of drug development lies in comprehending how these targets interact with cancer cells, influencing their growth and survival
• The trajectory of novel drug and biomarker development extends beyond target identification, encompassing pre-clinical and clinical trials
• Trials rigorously evaluate the safety, efficacy, and pharmacokinetics of these agents, seeking to establish optimal doses, treatment schedules, and combination therapies that maximize therapeutic benefits while mitigating side effects
• Pharmacology basic and translational research, clinical trials, bioinformatics research, machine learning, meta-analysis, and drug development based on biomarkers of solid tumors.
• Explore the pharmacological mechanisms of drug therapy for solid tumors according to relevant targets and pathways.
Keywords: solid tumors, biomarkers, targets, medicine, cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
